Janelle Hart

In a recent study, presented at the 2021 AUA Annual Meeting, Peter Chin, MD, and co-authors assessed the efficacy of the investigational Zenflow Spring System in treating patients with BPH.

In a recent study presented at the 2021 AUA Annual Meeting, Kevin T. McVary, MD, FACS, and co-authors assessed the 5-year outcomes of Rezum water vapor thermal therapy in patients with BPH, specifically focusing on erectile and ejaculatory function.

In a recent study presented at the 2021 AUA Annual Meeting, Michael B. Chancellor, MD, and co-authors conducted a study that assessed the efficacy of autologous muscle derived cells for urinary sphincter repair in treating women with SUI.

An aggressive treatment, such as bladder removal, may be necessary in patients with early stage micropapillary bladder cancer because the disease may behave more like late-stage conventional urothelial carcinoma.

In this interview, Kevin Zorn, MD, discusses 3-year results from a study of robot-assisted Aquablation procedures in treating men with large prostates.

"The challenges involved in medical stone prevention are first, making the diagnosis with current protocols," says Glenn M. Preminger, MD.

In a study presented at the 2021 AUA annual meeting, Bilal Chughtai, MD, and co-authors implemented the new iTind system, designed to treat patients with LUTS secondary to BPH by implanting the device via a cystoscopic procedure.

In this interview, Steven A. Kaplan, MD, discusses notable findings from a recent study evaluating multiple BPH treatments as well as his own patient selection process for treatments.

"The promising rPFS and overall survival data support further evaluation of pembrolizumab plus olaparib in molecularly unselected patients with mCRPC who received prior docetaxel treatment,” the authors concluded.

In a study presented at the 2021 AUA Annual Meeting, Andrew Higgins, MD, and co-authors implemented electrocautery protocols to mitigate blood loss among patients who undergo Aquablation.

"The take-home message is that Optilume is safe, and that it's superior to standard DVIU or dilation for the treatment of recurrent anterior urethral strictures that are less than 3 cm in length," says Sean P. Elliott, MD, MS, FACS.

The MV140 vaccine "will be a game changer for women's health in the future," says J. Curtis Nickel, MD.

“These studies highlight important research in better predicting the behavior and outcomes of prostate cancer in African American men compared to men of other racial and ethnic groups,” says Brian T. McNeil, MD, MBA, FACS.

In this interview, Shore discusses findings of a study of darolutamide (Nubeqa) presented at the 2021 AUA annual meeting and their significance for patients with nonmetastatic castration-resistant prostate cancer.

In comparison to the cohort of highly trained dogs, the eNose instrument was found to have sensitivity of 85.2% and specificity of 79.1%.

“Asian men had the lowest rates of ED treatments compared to Caucasian men, regardless of modality of treatment,” says Tony Chen, MD.

The combination is now being explored in a phase 3 trial.

In this interview, Dean Elterman, MD, discusses Rezum and Aquablation abstracts he presented at the 2021 AUA Annual Meeting and provides his overall perspective on the treatment of BPH.

Patients who received mid-urethral slings at higher-volume medical centers had a lower risk of reoperation.

In this interview, urologist Matthew J. Allaway, MD, gives an overview of transrectal vs transperineal biopsies, discusses how his own cancer battle influenced his professional path, and how his PrecisionPoint system aids in the detection of prostate cancer.

"Televisits are a valuable form of health care, and I think it could be better reimbursed even after the pandemic ends, especially for telephone visits," says Christina Shin, BA.

Eligible participants will receive free genetic testing and counseling that will determine potential gene mutations and propose plans for treatment.

“These results may help guide policy making, developing quality indicators, and developing targeted continued education for physician and patients embarking on active surveillance to establish realistic expectations,” said Antonio Finelli, MD.

"Patients with BPH appear to have a potential protective factor against prostate cancer," said Kiran Nandalur, MD.

“In children and youth, there really [hasn’t] been an examination of the impact of gender-affirming care on mental health care use patterns," said Elizabeth Hisle-Gorman, MSW, PhD.

"Interestingly, we found that the prevalence of male infertility in men with type 1 diabetes was 1.5%, comprising 33 out of more than 2000 men diagnosed with type 1 diabetes who reported male infertility," says Omer A. Raheem, MD, MSc, in this interview.

“For harder, more aggressive stones, I'm more likely to use the Trilogy based on the results of the study. If I have a softer, easier stone, I prefer the lightness of the ShockPulse," said lead study investigator Amy E. Krambeck, MD.

In an interview with Urology Times, Kara L. Watts, MD, discusses her research and clinical experience with telemedicine in urology.

Results from the phase 2 TALAPRO-1 study published in the Lancet Oncology show favorable antitumor activity with talazoparib in heavily pretreated patients with metastatic castration-resistant prostate cancer and DDR-HRR gene alterations.